8-Methyl-, phenyl-, or substituted phenyl-11,12-secoprostaglandins

ABSTRACT

This invention relates to 11,12-secoprostaglandins and processes for their manufacture. These compounds have prostaglandin-like biological activity and are particularly useful as renal vasodilators, for the treatment of hypertension, and for the prevention of thrombus formation.

This is a division of application Ser. No. 584,555 filed June 6, 1975now U.S. Pat No. 3,991,087; which in turn is a continuation-in-part ofSer. No. 424,501 filed Dec. 13, 1973, now abandoned.

SUMMARY OF THE INVENTION

This invention relates to novel 11,12-secoprostaglandins. Thesecompounds can be represented by the following structural formula:##STR1## wherein R is selected from the group consisting of carboxy anda carboxy salt being formed from a pharmaceutically acceptable cation,such as metal cations derived from alkali metals, alkaline earth metals,and amines such as ammonia, primary and secondary amines, and quaternaryammonium hydroxides. Especially preferred metal cations are thosederived from alkali metals, e.g., sodium, potassium, lithium, and thelike, and alkaline earth metals, e.g., calcium, magnesium, and the like,and other metals, i.e., aluminum, iron, and zinc.

Pharmaceutically acceptable cations derived from primary, secondary, ortertiary amines, or quaternary ammonium hydroxides are methylamine,dimethylamine, trimethylamine, ethylamine, N-methylhexylamine,benzylamine, α-phenethylamine, ethylenediamine, piperidine, morpholine,pyrrolidine, 1,4-dimethylpiperazine, ethanolamine, diethanolamine,triethanolamine, tris(hydroxymethyl)aminomethane, N-methylglucamine,N-methylglucosamine, ephedrine, procaine, tetramethylammonium hydroxide,tetraethylammonium hydroxide, benzyl trimethylammonium and the like.

R is also selected from alkoxycarbonyl (-COOY) wherein Y is alkyl having1-10 carbon atoms, carbamoyl (--CONH₂); substituted carbamoyl (--CONR⁵R⁶ wherein R⁵ and R⁶ are selected from the group consisting of hydrogen,lower alkyl having 1-4 carbon atoms and diloweralkylaminoalkyl having4-7 carbon atoms.

A is selected from the group consisting of ethylene (--CH₂ CH₂ --),trimethylene (--CH₂ CH₂ CH₂ --), α-methylethylene (--CH₂ -CH(CH₃)--),β-methylethylene (--CH(CH₃)CH₂ --), α,α-dimethylethylene (--CH₂ -C(CH₃)₂--), β,β-dimethylethylene (--C(CH₃)₂ CH₂ --) and oxymethylene (--O-CH₂--). (Note that when A consists of a two carbon bridge, the term "α"refers to the carbon adjacent to R, while "β" refers to the other carbonatom.)

Q is chloro, bromo, methyl, phenyl, or substituted phenyl.

R¹ is independently selected from the group consisting of hydrogen andmethyl.

R² is selected from the group consisting of hydrogen, and lower alkanoylof 1-5 carbon atoms, e.g., formyl, acetyl, propionyl, butyryl,isobutyryl, valeryl, pivaloyl and the like.

R³ is independently selected from the group consisting of hydrogen andmethyl.

R₄ is selected from the group consisting of hydrogen, lower alkyl of 1-4carbon atoms, either straight or branched, (e.g., methyl, ethyl, propyl,isopropyl, butyl, tert-butyl) and 2,2,2-trifluoroethyl. In addition,when R⁴ is lower alkyl and R¹ is methyl, they can be joined together(with abstraction of hydrogen) to form a carbocyclic ring with from 6 to9 members. Also, when R⁴ is lower alkyl and R¹ is hydrogen, R⁴ can bejoined to the carbon atom bearing R¹ and OR² to form a carbocyclic ringwith from 5 to 8 members.

A preferred embodiment of this invention relates to the11,12-secoprostaglandins having the following general formula: ##STR2##wherein A' is ethylene or oxymethylene;

R¹, r², and Q are as defined above; and R⁷ is ethyl, isopropyl, orbutyl.

It is to be noted that the carbon bearing R¹ and OR² is asymmetric. Thisinvention covers stereo-isomers in which this asymmetric center isexclusively in either one or the other of the two possibleconfigurations, R and S. This invention also contemplates that theasymmetric carbon bearing the Q substituent also be prepared in each ofits possible configurations.

BACKGROUND OF THE INVENTION

The compounds of formula I are described as 11,12-secoprostaglandinsbecause of their structural relationship to the naturally occurringprostaglandins.

The prostaglandins constitute a biologically prominent class ofnaturally occurring, highly functionalized C₂₀ fatty acids which areanabolized readily in a diverse array of mammalian tissues from threeessential fatty acids; namely, 8,11,14-eicosatrienoic acid, 5,8,11,14-eicosatetraenoic acid and 5,8,11,14,17-eicosapentaenoic acid. Eachknown prostaglandin is a formal derivative of the parent compound,termed "prostanoic acid;" the latter is a C₂₀ fatty acid covalentlybridged between carbons 8 and 12 such as to form a trans,vicinally-substituted cyclopentane in which the carboxy-bearing sidechain is "alpha" or below the plane of the ring and the other side chainis "beta" or above the plane of the ring as depicted in formula III:##STR3##

The six known primary prostaglandins, PGE₁, PGE₂, PGE₃, PGF₁α ,PGF₂α ,and PGF₃α resulting directly from anabolism of the above cited essentialfatty acids via the action of prostaglandin synthetase, as well as thethree prostaglandins resulting from in vivo dehydration of the PGE's,i.e., PGA₁, PGA₂, and PGA₃, are divided into three groups; namely, thePGE, PGF, and PGA series on the basis of three distinct cyclopentanenuclear substitution patterns as illustrated as follows:

    ______________________________________                                         ##STR4##                                                                                  ##STR5##                                                                                     ##STR6##                                          PGE nucleus PGF.sub.α nucleus                                                                      PGA nucleus                                        ______________________________________                                        PG          R.sub.a        R.sub.b                                            ______________________________________                                        E.sub.1, F.sub.1, A.sub.1                                                                 ##STR7##                                                                                      ##STR8##                                          E.sub.2, F.sub.2, A.sub.2                                                                 ##STR9##                                                                                      ##STR10##                                         E.sub.3, F.sub.3, A.sub.3                                                                 ##STR11##                                                                                     ##STR12##                                         E.sub.o, F.sub.o, A.sub.o                                                                 ##STR13##                                                                                     ##STR14##                                     

It should be noted that the Arabic subscripts designate the number ofcarbon-carbon double bonds in the designated compound and that the Greeksubscript used in the PGF series designates the sterochemistry of theC-9 hydroxyl group.

Although the prostaglandins were discovered independently in themid-1930's by Goldblatt [J. Chem. Soc. Chem. Ind. Lond., 52, 1056(1933)] in England and Von Euler [Arch. Exp. Path. Pharmark., 175, 78(1934)] in Sweden, these complex natural products received littleattention from the scientific community until the early 1960's whichcoincides with the advent of modern instrumentation (e.g., massspectrometry) which, in turn, was requisite for their successfulisolation and structural elucidation by Bergstrom and colleagues [seeAngew. Chem. Int. Ed., 4, 410 (1965) and references cited therein for anaccount of this work]. Within the last decade, a massive internationalscientific effort has been expended in developing both biosynthetic andchemical routes to the prostaglandins and, subsequently, ininvestigating of their biological activities. During this period,prostaglandins have been shown to occur extensively in lowconcentrations in a myriad of mammalian tissues where they are bothrapidly anabolized and catabolized and to exhibit a vast spectrum ofpharmacological activities including prominent roles in (a) functionalhyperemia, (b) the inflammatory response, (c) the central nervoussystem, (d) transport of water and electrolytes, and (e) regulation ofcyclic AMP. Further details concerning the prostaglandins can be foundin recent reviews of their chemistry [J. E. Pike, Fortschr. Chem. Org.Naturst., 28, 313 (1970) and G. F. Bundy, A. Rep. in Med. Chem., 7, 157(1972)], biochemistry [J. W. Hinman, A. Rev. Biochem., 41, 161 (1972)],pharmacology [J. R. Weeks, A. Rev. Pharm., 12, 317 (1972)],physiological significance [E. W. Horton, Physiol. Rev., 49, 122 (1969)]and general clinical application [J. W. Hinman, Postgrad. Med. J., 46,562 (1970)].

The potential application of natural prostaglandins as medicinallyuseful therapeutic agents in various mammalian disease states is obviousbut suffers from three formidable major disadvantages, namely, (a)prostaglandins are known to be rapidly metabolized in vivo in variousmammalian tissues to a variety of metabolites which are devoid of thedesired original biological activities, (b) the natural prostaglandinsare inherently devoid of biological specificity which is requisite for asuccessful drug, and (c) although limited quantities of prostaglandinsare presently produced by both chemical and biochemical processes, theirproduction cost is extremely high; and, consequently, their availabilityis quite restricted.

Our interest has, therefore, been to synthesize novel compoundsstructurally related to the natural prostaglandins but with thefollowing unique advantages: (a) simplicity of synthesis leading to lowcost of production; (b) specificity of biological activity which may beeither of a prostaglandin-mimicking or prostaglandin-antagonizing type;(c) enhanced metabolic stability. The combination of these advantagesserves to provide effective, orally and parenterally active therapeuticagents for the treatment of a variety of human and animal diseases.Included are applications in renal, cardiovascular, gastrointestinal,respiratory, and reproductive systems, and in the control of lipidmetabolism, inflammation, blood clotting, skin diseases, and certaincancers.

More specifically, in the clinic, prostaglandin agonists can function asagents for improving renal function (e.g., renal vasodilation),antihypertensives, anti-ulcer agents, agents for fertility control,antithrombotics, antiasthmatics, antilipolytics, antineoplastic agents,and agents for the treatment of certain skin diseases.

Prostaglandin antagonists can function as anti-inflammatory agents,anti-diarrheal agents, antipyretics, agents for prevention of prematurelabor, and agents for the treatment of headache.

The compounds of the present invention are useful as pharmaceuticallyactive compounds. Thus, these compounds are orally active in thetreatment of conditions which are responsive to the actions of thenatural prostaglandins. It is of course necessary to determine byroutine laboratory testing which of the compounds of the presentinvention are most suitable for a specific end use. Some of thecompounds of the invention have prostaglandin-like activity in that theymimic the effect of prostaglandin E₁ in stimulating the formation ofcyclic AMP in the mouse ovary in vitro.

The compounds of this invention are particularly useful for thetreatment of hypertension. Certain of the compounds of the presentinvention are useful in lowering blood pressure in individuals withblood pressure higher than normal. Thus, for example, the compound8-acetyl-12-hydroxy-8-phenylheptadecanoic acid is found to be effectivein lowering blood pressure in laboratory animals (rats) which have bloodpressure higher than that normally observed in such test animals.

Because of their biological activity and ready accessibility, thecompounds of the invention are also useful in that they permit largescale animal testing, useful and necessary to understanding of thesevarious disease conditions such as kidney impairment, ulcers, dwarfismcaused by poorly-functioning pituitary glands, stroke (thrombusformation), and the like. It will be appreciated that not all of thecompounds of this invention have these biological activities to the samedegree, but the choice of any particular ones for any given purpose willdepend upon several factors including the disease state to be treated.

The compounds of this invention can be administered either topically orsystemically, i.e., intravenously, subcutaneously, intramuscularly,orally, rectally, or by aerosolization in the form of sterile implantsfor long action. They can be formulated in any of a number ofpharmaceutical compositions and non-toxic carriers to this end.

The pharmaceutical compositions can be sterile injectable suspensions orsolutions, or solid orally administrable pharmaceutically acceptabletablets or capsules; the compositions can also be intended forsublingual administration, or for suppository use. It is especiallyadvantageous to formulate compositions in dosage unit forms for ease andeconomy of administration and uniformity of dosage. "Dosage unit form"as a term used herein refers to physically discrete units suitable asunitary dosages for animal and human subjects, each unit containing apredetermined quantity of active material calculated to produce thedesired biological effect in association with the requiredpharmaceutical means.

Illustratively, a sterile injectable composition can be in the form ofaqueous or oleagenous suspensions or solutions.

The sterile injectable composition can be aqueous or oleagenoussuspension or solution. Suspensions can be formulated according to theknown art using suitable dispersing and wetting agents and suspendingagents. Solutions are similarly prepared from the salt form of thecompound. For the laboratory animals, we prefer to use incompleteFreund's adjuvant or sterile saline (9%) as carrier. For humanparenteral use, such as intramuscularly, intravenously, or by regionalperfusion, the diluent can be a sterile aqueous vehicle containing apreservative; for example, methylparaben, propylparaben, phenol, andchlorobutanol. The aqueous vehicle can also contain sodium chloride,preferably in an amount to be isotonic; as well as a suspending agent,for example, gum arabic, polyvinyl pyrrolidone, methyl cellulose,acetylated monoglyceride (available commercially as Myvacet fromDistillation Products Industry, a division of Eastman Kodak Company),monomethyl glyceride, dimethyl glyceride or a moderately high molecularweight polysorbitan (commercially available under the tradenames Tweenor Span from Atlas Powder Company, Wilmington, Delaware). Othermaterials employed in the preparation of chemotherapeutic compositionscontaining the compound may include glutathione, 1,2-propanediol,glycerol and glucose. Additionally, the pH of the composition isadjusted by use of an aqueous solution such astris(hydroxymethyl)aminomethane (tris buffer).

Oily pharmaceutical carriers can also be used, since they dissolve thecompound and permit high doses. Many oily carriers are commonly employedin pharmaceutical use, such as, for example, mineral oil, lard,cottonseed oil, peanut oil, sesame oil, or the like.

It is preferred to prepare the compositions, whether aqueous or oils, ina concentration in the range of from 2-50 mg./ml. Lower concentrationsthan 50 mg./mg. are difficult to maintain and are preferably avoided.

Oral administration forms of the drug can also be prepared forlaboratory animals or human patients provided that they are encapsulatedfor delivery in the gut. The drug is subject to enzymatic breakdown inthe acid environment of the stomach. The same dosage levels can be usedas for injectable forms; however, even higher levels can be used tocompensate for biodegradation in the transport. Generally, a solid unitdosage form can be prepared containing from 0.5 mg. to 25 mg. activeingredient.

Whatever the mode of administration, doses in the range of about 0.10 to20 milligrams per kilogram of body weight administered one to four timesper day are used. The exact dose depending on the age, weight, andcondition of the patient, and the frequency and route of administration.

The low cost and ready accessibility of the compounds of this inventionmake them particulaly promising for applications in veterinary medicinein which field their utilities are comparable to those in humanmedicine.

There are a number of inter-related processes useful in preparing thecompounds of Formula I. These can all be described as the sub-synthesisof each of the three main moieties of the molecule, i.e., the (CH₂)₄ ARchain, the ##STR15## chain, and the Q group which are attached to anasymmetric carbon, and their reaction(s) to form the desired endproduct.

One major process utilizes as starting materials compounds in which onlythe Q group is lacking, i.e., ##STR16##

When using these compounds of Formula IV, R is defined to be either acarboxy group or a blocked carboxy group, i.e., a lower alkyl esterwherein lower alkyl is 1-6 carbon atoms. Compounds of this structure arenot part of this invention, but are claimed in co-pending U.S. Ser. No.302,365, filed October 30, 1972, now abandoned in the names of Cragoe,Bicking and Smith, and in a continuation-in-part application of thatapplication, Ser. No. 389,901, filed Aug. 23, 1973, now abandoned, andin its second continuation-in-part application, Ser. No. 669,118 filedMar. 22, 1976, in the names of the same inventors.

These starting materials of Formula IV where R is carboxy are reactedwith cupric chloride and lithium chloride to yield compounds of FormulaI wherein Q is chloro; and with cupric bromide and lithium bromide toyield compounds wherein Q is bromo. When compounds wherein Q is methylare desired, the compounds of Formula IV where R is blocked carboxy asdescribed above are first treated with molecular bromine. The productsof this reaction (Q equals bromo) are reacted with dimethyl copperlithium (generated in situ) to give products of Formula IV where Q ismethyl. The carboxy-blocking ester function can subsequently be removedby basic hydrolysis.

To prepare compounds of Formula I wherein Q is phenyl, a sequentialsynthesis of the molecule is employed.

First, the starting material is one of the following reagents: ##STR17##wherein X is halogen, preferably chlorine or bromine, and R³ and R⁴ areas defined in Formula I.

Reagent V is used to obtain final compounds of Formula I wherein R¹ ishydrogen; the reagent VI is used when R¹ is methyl in the desired finalproduct.

Either of the desired reagents is reacted with phenyl acetone or asubstituted phenyl acetone, viz., ##STR18## wherein W indicates anoptional substituent (or substituents). Substituents which are suitableare halogens, e.g., chlorine, bromine, iodine, or fluorine; lower alkyl,e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, and the like; loweralkoxy, as methoxy, ethoxy, propoxy, and the like. The substituent(s)can be ortho-, meta-, or para-position, and mono- or poly-substitutioncan be made. When there is poly-substituent, the substituents need notnecessarily be the same.

The reaction between compounds V or VI and VII is conducted in thefollowing manner:

Compound VII is treated with an equivalent of base such as sodiumhydride, sodium ethoxide, sodium amide, or the like. The enolate anionthus produced is alkylated by reaction with either compound V or VI.This reaction is conducted in an inert solvent such asdimethylformamide, dimethylformamide:benzene (1:1) or diglyme, at atemperature ranging from 40° to 120° C. The reactants are employed inapproximately equimolar amounts. The reaction is complete in 2-4 hours.The intermediate product(s) are then isolated: ##STR19## wherein W, R³,and R⁴ are as defined.

Either of these compounds VIII or IX are then treated with an equimolaramount of base, as NaH, NaOC₂ H₅, NaNH₂, and then alkylated with thereagent:

    X-(CH.sub.2).sub.4 -A-COOR.sup.8                           X

wherein X is halogen, preferably bromine or chlorine, A is as defined inFormula I, and R⁸ is lower alkyl having 1-5 carbon atoms, preferablyethyl. This reaction is conducted in a similar manner as before, i.e.,the reagents are employed in approximately equimolar amounts; thesolvent employed is inert, such as DMF, DMF in benzene (1:1) or diglyme.Temperature can be between about 60° C. to 120° C. The reaction iscomplete within 12-72 hours.

The products isolated are the following: ##STR20## These are furthertreated to yield the final product of Formula I.

For example, compound XI is hydrogenated to remove the protecting)-benzyl group and then subjected to mild basic hydrolysis to hydrolyzethe ester function and remove R⁸.

Compound XII is hydrated using a oxymercuration-demercuration process inwhich the compound is treated with mecuric acetate in aqueoustetrahydrofuran for a prolonged period to effect oxymercuration followedby treatment of the reaction mixture with sodium borohydride to effectdemercuration. This product is: ##STR21## Mild basic hydrolysis (NaOH isaqueous methanol or ethanol) of the ester function of compound XIIIyields the compounds of Formula I.

It should be pointed out that the exact order of reacting either ofcompounds V or VI with VII, then with X, is not critical, either V or VIor X can be the first reactant. Subsequently, the other of the reactantsis reacted with the recovered intermediate. The order described is ourpreferred route, however.

It can be advantageous from a therapeutic standpoint to preparecompounds of Formula I in which the various asymmetric carbons areexclusively in a certain configuration. For instance, the asymmetriccarbon bearing the R¹ and OR² group, in the natural prostaglandins, isin the S configuration; inversion of this center usually produces areduction in biological activity, although sometimes a marked increasein biological specificity results. Compounds exclusively R and S can beprepared in these processes by using starting materials or intermediateswhich are optically active, i.e., resolved into their R and S isomericforms.

These products as prepared in these processes can be derivatized in avariety of ways to yield other products of Formula I.

1. The fundamental processes yield compounds where R is carboxy. Toobtain carboxy salts the acid products are dissolved in a solvent suchas ethanol, methanol, glyme and the like and the solution treated withan appropriate alkali or alkaline earth hydroxide or alkoxide to yieldthe metal salt, or with an equivalent quantity of ammonia, amine orquaternary ammonium hydroxide to yield the amine salt. In each instance,the salt either separates from the solution and may be separated byfiltration or, when the salt is soluble it may be recovered byevaporation of the solvent. Aqueous solutions of the carboxylic acidsalts can be prepared by treating an aqueous suspension of thecarboxylic acid with an equivalent amount of an alkaline earth hydroxideor oxide, alkali metal hydroxide, carbonate or bicarbonate, ammonia, anamine, or a quaternary ammonium hydroxide.

To obtain carboxy esters (i.e., compounds where R is alkoxycarbonyl) theacid products are treated in ether with an ethereal solution of theappropriate diazoalkane. For example, methyl esters are produced byreaction of the acid products with diazomethane. To obtain productswhere R is carbamoyl, substituted carbamoyl or carbazolyl the acidproduct is first converted to an active Woodward ester. For example, theacid product can be made to react with N-tert-butyl-5-methylisoxazoliumperchlorate in acetonitrile in the presence of a base such astriethylamine to yield an active ester in which R is ##STR22## Activeesters of this type can be reacted with ammonia to yield products ofFormula I where R is carbamoyl, with primary or secondary amines ordi-lower-alkylaminoalkylamines to yield products where R is substitutedcarbamoyl, i.e., --CONR⁶ R⁷, and with hydrazine to yield products whereR is carbazolyl.

2. The fundamental processes yield products where R² is hydrogen. Incompounds containing no additional hydroxy group and in which R¹ ishydrogen, reaction with formic acid, acetic anhydride, propionicanhydride, butyric anhydride, isobutyric anhydride, valeric anhydride,pivalic anhydride and the like, without solvent and at temperatures from25° to 60° C., gives compounds wherein R² is formyl, acetyl, propionyl,butyryl, isobutyryl, valeryl, and pivaloyl, respectively.

Methods for obtaining optical antipodes of the compounds of thisinvention have been described supra, whereby one of the components ofthe molecule is preresolved prior to its assembly into the wholemolecule. Other methods also can be employed; for example, mixtures ofracemates may be separated by taking advantage of the physiochemicaldifferences between the components using chromatography and/orfractional crystallization. The racemic products and intermediates ofthis invention can be resolved into their optically active components byany one of a number of methods of resolution which are well described inthe chemical literature.

Those compounds which are carboxylic acids can be converted to thediastereoisomeric salts by treatment with an optically active base suchas + or - α-methylbenzylamine, + or - α-(1-naphthyl)-ethylamine,bromine, cinchonine, cinchonidine, or quinine. These diastereoisomericsalts can be separated by fractional crystallization.

The carboxylic acids of this invention also can be converted to estersusing an optically active alcohol, such as, estradiol-3-acetate, or d-or 1-methanol and the diastereoisomeric esters resolved bycrystallization or by chromatographic separation.

Racemic carboxylic acids also may be resolved by reverse phase andabsorption chromatography using an optically active support andabsorbent.

Compounds of this invention which contain free hydroxyl groups can beesterified with acid chlorides or anhydrides derived from opticallyactive acids, such as, (═)-10-camphorsulfonic acid,(═)-α-bromocamphorsulfonic acid, or d- or 1-6,6'-dinitrodiphenic acid toform esters which can be resolved by crystallization.

Another method of obtaining pure optical isomers involves incubation ofthe racemic mixture with certain microorganisms such as fungi, byprocesses well established in the art, and recovering the product formedby the enzymatic transformation.

The methods describes supra are especially effective if one applies theprocess to a compound where one asymmetric center has been preresolvedby the techniques already described.

The preparation of the intermediates V, VI and X is described inco-pending U.S. Ser. No. 302,365, now abandoned, filed Oct. 30, 1972 inthe names of Cragoe, Bicking and Smith in a continuation-in-partapplication, U.S. Ser. No. 389,901, filed Aug. 23, 1973, now abandoned,and its second C-I-P application Ser. No. 669,118 filed Mar. 22, 1976.

The intermediates VII are prepared by a process which has been describedin the chemical literature (R.V. Heinzelman, "Organic Syntheses" Coll.Vol. IV, John Wiley & Sons, Inc., New York, New York, p. 573) and whichmay be outlined as follows and wherein W is as described previously:##STR23##

EXAMPLE 1 Preparation of 8-Acetyl-8-chloro-12-hydroxyheptadecanoic AcidStep A: Preparation of Ethyl 8-Tert.-butoxycarbonyl-9-oxodecanoate

A suspension of 57% sodium hydride in mineral oil (37.05 g. net wt.;0.88 mole) in a solvent mixture of benzene (400 ml.) anddimethylformamide (400 ml.) is treated, dropwise, over 30 minutes withtert.-butyl acetoacetate (126.56 g.; 0.80 mole). Stirring is continuedfor an additional 30 minutes. Then ethyl 7-bromoheptanoate (208.50 g.;0.88 mole) is added, dropwise, over 30 minutes and the mixture is heatedat 100° C. for 2 1/2 hours.

The cooled reaction mixture is treated with water (1600 ml.) and theorganic layer is separated. The aqueous layer is extracted with ether.The combined organic solutions are washed with saturated sodium chloridesolution and then dried over anhydrous sodium sulfate. The solvents areremoved under vacuum and the residual oil is distilled to give 158.6 g.(63%) of 8-tert.-butoxycarbonyl-9-oxodecanoate as a yellow oil, b.p.175°-177°/0.5 mm.

Step B: Preparation of 1-Chloro-4-nonanone

To the Grignard reagent prepared from a mixture of amyl bromide (226.59g.; 1.5 moles) and magnesium (36.48 g.; 1.5 moles) in ether (1000 ml.)is added, dropwise, during 1 hour, 4-chlorobutyronitrile (155.34 g.; 1.5moles). Stirring is continued for an additional 1 hour. The reactionmixture is poured into a mixture of finely crushed ice (1000 g.) andconcentrated hydrochloric acid (750 ml.). The ether layer is separatedquickly and discarded. The aqueous layer is heated on a steam bath forone hour to hydrolyze the intermediate imine and cause the separation ofthe ketone as an oil. After cooling, the oil is extracted with ether andthe combined extracts are washed with saturated sodium chloride solutionand dried over anhydrous sodium sulfate. The solvent is removed undervacuum and the residual oil is distilled to give 69.0 g. (26%), of1-chloro-4-nonanone as a colorless oil, b.p. 115°-117°/14 mm.; pmr(CDCl₃) δ 0.90 (3H,t), 3.56 (2H,t,CH₂ Cl).

Step B(2): Preparation of 1-Chloro-4-nonanol

A suspension of sodium borohydride (6.62 g.; 0.175 mole) and sodiumhydroxide (1.3 g.) in ethanol (310 ml.) is treated, dropwise, over 1hour with 1-chloro-4-nonanone (61.40 g.; 0.349 mole) while thetemperature is maintained at 45°-50°. Stirring is continued for 1 hour,longer without external cooling.

The reaction mixture is acidified with concentrated hydrochloric acid tothe Congo red endpoint and then the ethanol is removed under reducedpressure. The residue is treated with water (200 ml.) and the resultingoil is extracted with ether. The combined extracts are washed withsaturated sodium chloride solution and dried over anhydrous sodiumsulfate. The solvent is removed under vacuum to give 1-chloro-4-nonanolas a light yellow residual oil, yield 58.85 g.; ir (neat) 3400 cm⁻¹.

Step B(3) Preparation of 1-Chloro-4-acetoxynonane

A mixture of 1-chloro-4-nonanol (111.99 g.; 0.627 mole) and aceticanhydride (128.0 g.; 1.254 moles) is heated on a steam bath for 1 1/2hours.

The volatile materials are removed under reduced pressure and theresidual oil is distilled to give 88.6 g.(64%) of1-chloro-4-acetoxynonane as a colorless oil, b.p. 130°-133°/14 mm.; pmr(CDCl₃) δ 0.89 (3H,t), 2.02 (3H, s CH₃ COO), 3.53 (2H,t CH₂ Cl), 4.89(1H,m). Anal. Calcd. for C₁₁ H₂₁ ClO₂ : C, 59.85; H, 9.59 Found: C,59.87; H, 9.67.

Step B (4): Preparation of Ethyl8-Acetyl-8-tert.-butoxycarbonyl-12-acetoxyheptadecanoate

A suspension of 57% sodium hydride in mineral oil (3.03 g. net wt.,0.072 mole) in a solvent mixture of benzene (40 ml.) anddimethylformamide (40 ml.) is treated, dropwise, over a period of 30minutes with ethyl 8-tert.-butoxycarbonyl-9-oxodecanoate (20.41 g.,0.065 mole). Stirring is continued for an additional period of 30minutes. Then 1-chloro-4-acetoxynonane (15.80 g., 0.072 mole) is added,dropwise, over 30 min. Potassium iodide (50 mg.) is added and themixture heated at 100° for 66 hours.

The reaction mixture is cooled, treated with water (160 ml.) and theorganic layer separated. The aqueous layer is extracted with ether. Thecombined organic extracts are washed with a saturated aqueous sodiumchloride solution and then dried over anhydrous sodium sulfate. Thesolvents are removed by evaporation in vacuo to give a residual oil ofethyl 8-acetyl-8-tert.-butoxycarbonyl-12-acetoxyheptadecanoate. Theyield is 32.04 g.; pmr (CDCl₃) δ 0.90 (3H,t), 1.45 (9H,s), 2.02 (3H,sCH₃ COO), 2.12 (3H,s CH₃ CO), 4.13 (2H,q).

Step C: Preparation of Ethyl 8-Acetyl-12-acetoxyheptadecanoate

A mixture of ethyl8-acetyl-8-tert.-butoxycarbonyl-12-acetoxyheptadecanoate (32.04 g.;0.0643 mole), p-toluenesulfonic acid monohydrate (1.10 g.) and toluene(110 ml.) is heated under reflux for 18-22 hours. The CO₂ evolved isindicated by bubbling the gas into aqueous Ba(OH)₂.

The cooled reaction mixture is washed with saturated sodium bicarbonatesolution (25 ml.), saturated sodium chloride solution (2 × 25 ml.) andthen dried over anhydrous sodium sulfate. The solvent is removed undervacuum to give 26.69 g. (theory 25.63 g.) of a residual oil. The oil ispurified by column chromatography on silica gel with chloroform as aneluant. There is obtained 9.6 g. (38%) of ethyl8-acetyl-12-acetoxyheptadecanoate, pmr (CDCl₃) δ 0.90 (3H,t), 2.02 (3H,sCH₃ COO), 2.12 (3H,s CH₃ CO), 4.13 (2H,q), 4.84 (1H, m HCOCOCH₃).

Anal. Calcd. for C₂₃ H₄₂ O₅ : C, 69.31; H, 10.62; Found: C, 69.47; H,10.83.

Step D: Preparation of 8-Acetyl-12-hydroxyheptadecanoic Acid

Ethyl 8-acetyl-12-acetoxyheptadecanoate (12.21 g., 0.0306 mole) is addedto a solution of sodium hydroxide (3.67 g., 0.0918 mole) in water (17ml.) and methanol (153 ml.). The resulting solution is allowed to standfor 72 hours at 25° C. Most of the methanol is removed by evaporation invacuo. The residual solution is diluted with water (150 ml.) andextracted with ether. The aqueous layer is acidified to Congo red paperwith acid. The ether extract is washed with water.

The ether extract is dried over anhydrous sodium sulfate and evaporatedin vacuo to produce 9.65 g. (95%) of 8-acetyl-12-hydroxyheptadecanoicacid as a viscous yellow liquid. This material is purified by columnchromatography on silica gel with 2% methanol in chloroform as theeluant. There is obtained 6.9 g. (69%) of pure8-acetyl-12-hydroxyheptadecanoic acid as a colorless liquid, pmr (CDCl₃)δ 0.88 (3H,t), 2.12 (3H, S CH₃ CO), 3.64 (1H, m HCOH), 6.65 (2H, s OHand COOH).

Anal. Calcd. for C₁₉ H₃₆ O₄ : C, 69.47; H, 11.05; Found: C, 69.55; H,11.22.

Step E: Preparation of 8-Acetyl-8-chloro-12-hydroxyheptadecanoic Acid

A mixture of 8-acetyl-12-hydroxyheptadecanoic acid (16.4 g., 0.05 mole),cupric chloride dihydrate (20.5 g., 0.12 mole), lithium chloride (2.5g., 0.06 mole) and dimethylformamide (30 ml.) is heated with stirringfor 16 hours on the steam bath. The reaction mixture is then cooled andtreated with water. The oil which separates is taken up in ether, washedwith water and brine and dried over sodium sulfate. The ether isdistilled to leave the product as an orange oil, weight 19.3 g. Theproduct is purified by chromatography on silica gel with 2% methanol inchloroform as eluant. There is obtained 3.5 g. (19%) of8-acetyl-8-chloro-12-hydroxyheptadecanoic acid as a light yellow oil;pmr (CDCl₃) δ 0.88 (3H,t), 2.34 (3H,s CH₃ CO), 3.65 (1H,m HCOH).

Anal. Calcd. for C₁₉ H₃₅ ClO₄ : C, 62.88; H, 9.72; Found: C, 62.48; H,9.65.

By following exactly the same procedure but employing8-acetyl-12(R)-hydroxyheptadecanoic acid, there is obtained8-acetyl-8-chloro-12(R)-hydroxyheptadecanoic acid.

Similarly, by following exactly the same procedure but employing8-acetyl-12(S)-hydroxyheptadecanoic acid, there is obtained8-acetyl-8-chloro-12(S)-hydroxyheptadecanoic acid.

EXAMPLE 2 Preparation of 8-Acetyl-8-bromo-12-hydroxyheptadecanoic Acid

By following the procedure of Example 1, Step E, but substituting cupricbromide and lithium bromide for cupric chloride dihydrate and lithiumchloride, there is obtained 8-acetyl-8-bromo-12-hydroxyheptadecanoicacid as a viscous yellow oil purified by chromatography an silica gelwith 2% methanol in chloroform as the eluant.

EXAMPLE 3 Preparation of 8-Acetyl-12-hydroxy-8-phenylheptadecanoic AcidStep A: 1-Chloro-4-chloromethyoxynonane

A gentle stream of dry HCl gas is passed into a suspension of the crude1-chloro-4-nonanol (40.66 g., 0.23 mole) and S-trioxane (6.90 g., 0.077mole) for 14 hours. The resulting two-phase mixture is dried over CaCl₂.The CaCl₂ is removed by filtration and the filtrate is fractionallydistilled to obtain 1-chloro-4-chloromethoxynonane (19.05 g., 0.084mole, 31% yield, b.p. 140°-143°/14 mm.).

Step B: Preparation of 1-Chloro-4-benzyloxynonane

A solution of bromobenzene (13.18 g., 0.084 mole) in ether (50 ml.) isadded to a suspension of Mg (2.04 g., 0.084 mole) in ether (50 ml.)dropwise so as to maintain a gentle reflux. After complete addition ofthe bromobenzene, the mixture is heated on a steam bath for anadditional hour. The reaction mixture is then cooled to 5°-10° C. bymeans of an ice-water bath, and 1-chloro-4-chloromethoxynonane (19.05g., 0.084 mole) is added dropwise over 15 minutes. The resultingsuspension is stirred for 18 hours at room temperature. The reactionmixture is diluted with ether (100 ml.), cooled to 0°-5° C., and coldwater (75 ml.) is added with vigorous stirring while the temperature iskept below 5° C. Let stir at 0°-5° C. for about 15 minutes. The aqueousphase is separated from the ether phase (A), and the aqueous layer isextracted with ether (150 ml., B). Organic solution A is combined withB, washed with H₂ O (100 ml.), 5% K₂ CO₂ (100 ml.) again with H₂ O (100ml.), finally with saturated NaCl solution, and is dried over anhydrousNa₂ SO₄. Removal of the solvent is vacuo yields1-chloro-4-benzyloxyonane (19.28 g., 0.072 mole, 85.7% yield).

Step C: Preparation of 3-Phenyl-7-benzyloxy-2-dodecanone

Sodium hydride (1.7 g., 0.071 mole) is suspended in a mixture of benzene(50 ml.) and dimethylformamide (50 ml.) and phenylacetone (8.7 g., 0.071mole) is added dropwise. The resulting mixture is heated on the steambath for one hour and then cooled to room temperature.1-Chloro-4-benzyloxynonane (18.2 g., 0.071 mole) is added dropwise andthe mixture then heated and stirred on the steam bath for 24 hours. Themixture is cooled, poured into water (300 ml.) and the oily producttaken up in ether and dried over sodium sulfate. The solvent is removedin vacuo and the residual oil is fractionally distilled to yield 12.2 g.(46%) of 3-phenyl-7-benzyloxy-2-dodecanone, b.p. 184°-190°/0.1 mm Hg.

Step D: Preparation of Ethyl8-Acetyl-8-phenyl-12-benzyloxyheptadecanoate

Sodium hydride (0.8 g., 0.033 mole) is suspended in a mixture of benzene(50 ml.) and dimethylformamide (50 ml.) and3-phenyl-7-benzyloxy-2-dodecanone (12.1 g., 0.033 mole) is addeddropwise. The resulting mixture is heated on the steam bath for one hourand then cooled to room temperature. Ethyl 7-bromoheptanoate (8.8 g.,0.037 mole) is added dropwise and the mixture is heated on the steambath for 24 hours. The reaction mixture is cooled, poured into water(200 ml.) and the oily product taken up into ether and dried over sodiumsulfate. The solvent is distilled in vacuo to leave 14 g. of ethyl8-acetyl-8-phenyl-12-benzyloxyheptadecanoate as a yellow oil which isused in Step G without further purification.

Step E: Preparation of 8-Acetyl-8-phenyl-12-benzyloxyheptadecanoic Acid

A mixture of ethyl 8-acetyl-8-phenyl-12-benzyloxyheptadecanoate (14 g.,crude), sodium hydroxide (2.0 g., 0.05 mole) and methanol (150 ml.) isstirred for 48 hours. The methanol is removed in vacuo; and the residualoil is poured into H₂ O (100 ml.), acidified with 6 N HCl (100 ml.)extracted with ether, and the combined ether extracts dried overanhydrous Na₂ SO₄. The ether is removed in vacuo, and the residual oilis chromatographed through a silica gel column (95% CHCH₃ -5% MeOH) toobtain 8-acetyl-8-phenyl-12-benzyloxyheptadecanoic acid (1.43 g.,slightly impure).

Step F: Preparation of 8-Acetyl-8-phenyl-12-hydroxyheptadecanoic Acid

8-Acetyl-8-phenyl-12-benzyloxyheptadecanoic acid (1.42 g., slightlyimpure) is dissolved in EtOH (50 ml.), and is hydrogenated over 10%palladium on carbon at atmospheric pressure and 25° C. The hydrogenationis stopped after 2 hours, the catalyst is filtered off, and the solventis removed in vacuo to obtain the product as a crude viscous yellowishoil. This oil is chromatographed through a silica gel column (CHCl₃) toobtain 8-acetyl-8-phenyl-12-hydroxyheptadecanoic acid as a virtuallycolorless oil (350 mg.).

Anal. Calcd. for C₂₅ H₄₀ O₄ : C, 74.21; H, 9.97; Found: C, 74.38; H,9.80.

EXAMPLE 4 8-Acetyl-8-methyl-12-hydroxyheptadecanoic Acid Step A:Preparation of Ethyl 8-Acetyl-8-bromo-12-acetoxyheptadecanoate

Bromine (16.7 g., 0.104 mole) dissolved in carbon tetrachloride (100ml.) is added dropwise to a stirred solution of ethyl8-acetyl-12-acetoxyheptadecanoate (Example 1, Step C) (37.4 g., 0.094mole) in carbon tetrachloride (200 ml.) during one hour. The solvent isdistilled in vacuo. The residual oil is dissolved in ether and washedwith dilute sodium bicarbonate, water and brine and dried over sodiumsulfate. Evaporation of the ether leaves the crude bromo ester as ayellow oil weighing 43 g. It is purified by column chromatography onsilica gel with benzene as the eluant. This procedure serves to separatethe desired bromo ester from a small amount of a by-product, ethyl8-bromoacetyl-8-bromo-12-acetoxyheptadecanoate. Ethyl8-acetyl-8-bromo-12-acetoxyheptadecanoate is thus obtained as a paleyellow oil weighing 12.7 g. (28%.

Ethyl 8-Acetyl-8-methyl-12-acetoxy heptadecanoate Step B:

Cupruous iodide (7.1 g., 0.037 mole) is suspended in ether (150 ml.) anda 1.66 M solution of methyl lithium in ether (45 ml., 0.075 mole) isadded dropwise during 30 minutes. Ethyl8-acetyl-8-bromo-12-acetoxyheptadecanoate (11.9 g., 0.025 mole) is addeddropwise during 30 minutes. The temperature is kept at -4° C to -2° C.during these operations by means of a salt bath. Stirring is continuedat this temperature for another 30 minutes; then the mixture is stirredfor 2 hours without cooling. The reaction mixture is then treated with200 ml. of saturated ammonium chloride solution. the organic layer isseparated, washed with brine and dried over sodium sulfate. Distillationof the solvent in vacuo leaves the crude product as an orange oilweighing 9.2 g. The product is purified by column chromatography using250 g. of silica gel and chloroform as the eluant. Ethyl8-acetyl-8-methyl-12-acetoxyheptadecanoate is obtained as yellow viscousoil.

Step C: Preparation of 8-Acetyl-8-methyl-12-hydroxyheptadecanoic Acid

By following the hydrolytic procedure described in Example 1, Step D,but substituting an equimolar amount of ethyl8-acetyl-8-methyl-12-acetoxyheptadecanoate for the ethyl8-acetyl-12-acetoxyheptadecanoate of the example, there is obtained8-acetyl-8-methyl-12-hydroxyheptadecanoic acid as a colorless viscousoil.

In a like manner, the following compounds can be prepared:

EXAMPLE 5 Preparation of8-Acetyl-8-chloro-12-hydroxy-16-methylheptadecanoic Acid

By following the procedure described in Example 1, Step E, butsubstituting 8-acetyl-12-hydroxy-16-methylheptadecanoic acid for the8-acetyl-12-hydroxyheptadecanoic acid therein employed, there isobtained 8-acetyl-8-chloro-12-hydroxy-16-methylheptadecanoic acid.

EXAMPLE 6 Preparation of8-Acetyl-8-chloro-12-hydroxy-16,16-dimethylheptadecanoic Acid

By following the procedure described in Example 1, Step E, butsubstituting 8-acetyl-12-hydroxy-16,16-dimethylheptadecanoic acid forthe 8-acetyl-12-hydroxyheptadecanoic acid therein employed, there isobtained 8-acetyl-8-chloro-12-hydroxy-16,16-dimethylheptadecanoic acid.

EXAMPLE 7 Preparation of8-Acetyl-8-chloro-12-hydroxy-17,17,17-trifluoroheptadecanoic Acid

By following the procedure described in Example 1, Step E, butsubstituting 8-acetyl-12-hydroxy-17,17,17-trifluoroheptadecanoic acidfor the 8-acetyl-12-hydroxyheptadecanoic acid therein employed, there isobtained 8-acetyl-8-chloro-12-hydroxy-17,17,17-trifluoroheptadecanoicacid.

EXAMPLE 8 Preparation of8-acetyl-8-chloro-12-methyl-12-hydroxyheptadecanoic Acid

By following the procedure described in Example 1, Step E, butsubstituting 8-acetyl-12-methyl-12-hydroxyheptadecanoic acid for the8-acetyl-12-hydroxyheptadecanoic acid therein employed, there isobtained 8-acetyl-8-chloro-12-methyl-12-hydroxyheptadecanoic acid.

EXAMPLE 9 Preparation of8-Acetyl-8-chloro-12-hydroxy-13,13-dimethylheptadecanoic Acid

By following the procedure described in Example 1, Step E, butsubstituting 8-acetyl-12-hydroxy-13,13-dimethylheptadecanoic acid forthe 8-acetyl-12-hydroxy-heptadecanoic acid therein employed, there isobtained 8-acetyl-8-chloro-12-hydroxy-13,13-dimethylheptadecanoic acid.

EXAMPLE 10 Preparation of(5-Acetyl-5-chloro-9-hydroxytetradecyloxy)acetic Acid

By following the procedure described in Example 1, Step E, butsubstituting (5-acetyl-9-hydroxytetradecyloxy) acetic acid for the8-acetyl-12-hydroxyheptadecanoic acid therein employed, there isobtained (5-acetyl-5-chloro-9-hydroxytetradecyloxy) acetic acid.

EXAMPLE 11 Preparation of8-Acetyl-8-chloro-11-(1-hydroxycyclohexyl)undecanoic Acid

By following the procedure described in Example 1, Step E, butsubstituting 8-acetyl-11-(1-hydroxycyclohexyl) undecanoic acid for the8-acetyl-12-hydroxyheptadecanoic acid therein employed, there isobtained 8-acetyl-8-chloro-11-(1-hydroxycyclohexyl) undecanoic acid.

EXAMPLE 12 Preparation of2-Methyl-8-acetyl-8-bromo-12-hydroxyheptadecanoic Acid

By following essentially the procedure of Example 2 but substituting2-methyl-8-acetyl-12-hydroxyheptadecanoic acid for the8-acetyl-12-hydroxyheptadecanoic acid therein employed, there isobtained 2-methyl-8-acetyl-8-bromo-12-hydroxyheptadecanoic acid.

EXAMPLE 13 Preparation of3-Methyl-8-acetyl-8-bromo-12-hydroxyheptadecanoic Acid

By following essentially the procedure of Example 2, but substituting3-methyl-8-acetyl-12-hydroxyheptadecanoic acid for the8-acetyl-12-hydroxyheptadecanoic acid therein employed, there isobtained 3-methyl-8-acetyl-8-bromo-12-hydroxyheptadecanoic acid.

EXAMPLE 14 Preparation of2,2-Dimethyl-8-acetyl-8-bromo-12-hydroxyheptadecanoic Acid

By following essentially the procedure of Example 2, but substituting2,2-dimethyl-8-acetyl-12-hydroxyheptadecanoic acid for the8-acetyl-12-hydroxyheptadecanoic acid therein employed, there isobtained 2,2-dimethyl-8-acetyl-8-bromo-12-hydroxyheptadecanoic acid.

EXAMPLE 15 Preparation of3,3-Dimethyl-8-acetyl-8-chloro-12-hydroxyheptadecanoic Acid

By following essentially the procedure of Example 1, Step E, butsubstituting 3,3-dimethyl-8-acetyl-12-hydroxyheptadecanoic acid for the8-acetyl-12-hydroxyheptadecanoic acid therein employed, there isobtained 3,3-dimethyl-8-acetyl-8-chloro-12-hydroxyheptadecanoic acid.

EXAMPLE 16 Preparation of8-Acetyl-8-(4-fluorophenyl)-12-hydroxyheptadecanoic Acid

By following the procedure described in Example 3, but substituting(4-fluorophenyl) acetone for the phenylacetone employed in Step C, thereare obtained succesively from that point:3-(4-fluorophenyl)-7-benzyloxy-2-dodecanone (Step C); ethyl8-acetyl-8-(4-fluorophenyl)-12-benzyloxy-heptadecanoate (Step D);8-acetyl-8-(4-fluorophenyl)-12-benzyloxyheptadecanoic acid (Step E); and8-acetyl-8-(4-fluorophenyl)-12-hydroxyheptadecanoic acid (Step F).

EXAMPLE 17 Preparation of8-Acetyl-8-(2-methylphenyl)-12-hydroxyheptadecanoic Acid

By following the procedures described in Example 3, but substituting(2-methyphenyl) acetone for the phenylacetone employed in Step C, thereare obtained successively from that point:3-(2-methylphenyl)-7-benzyloxy-2-dodecanone (Step C); ethyl8-acetyl-8-(2-methylphenyl)-12-benzyloxyheptadecanoate (Step D);8-acetyl-8-(2-methylphenyl)-12-benzyloxyheptadecanoic acid (Step E); and8-acetyl-(2-methylphenyl)-12-hydroxyheptadecanoic acid (Step F).

EXAMPLE 18 Preparation of8-Acetyl-8-(3,4-dichlorophenyl)-12-hydroxyheptadecanoi Acid

By following the procedures described in Example 3, but substituting(3,4-dichlorophenyl) acetone for the phenylacetone employed in Step C,there are obtained successively from that point:3-(3,4-dichlorophenyl)-7-benzyloxy-2-dodecanone (Step C); ethyl8-acetyl-8-(3,4-dichlorophenyl)-12-benzyloxyheptadecanoic acid (Step E);and 8-acetyl-8-(3,4-dichlorophenyl)-12-hydroxyheptadecanoic acid (StepF).

EXAMPLE 19 Preparation of8-Acetyl-8-(4-methoxyphenyl)-12-hydroxyheptadecanoic Acid

By following the procedures described in Example 3, but substituting(4-methoxyphenyl) acetone for the phenylacetone employed in Step C,there are obtained successively from that point:3-(4-methoxyphenyl)-7-benzyloxy-2-dodecanone (Step C); ethyl8-acetyl-8-(4-methoxyphenyl)-12-benzyloxy-heptadecanoate (Step D);8-acetyl-8-(4-methoxyphenyl)-12-benzyloxyheptadecanoic acid (Step E);and 8-acetyl-8-(4-methoxyphenyl)-12-hydroxyheptadecanoic acid (Step F).

EXAMPLE 20 Preparation of 8-Acetyl-8-phenyl-12-hydroxynonadecanoic Acid

By following the procedures described in Example 3, but substituting inStep A 1-chloro-4-undecanol for the 1-chloro-4-nonanol therein employedthere are obtained successively: 1-chloro-4-chloromethoxyundecane (StepA); 1-chloro-4-benzyloxyundecane (Step B);3-phenyl-7-benzyloxy-2-tetradecanone (Step C); ethyl8-acetyl-8-phenyl-12-benzyloxynonadecanoate (Step D);8-acetyl-8-phenyl-12-benzyloxynonadecanoic acid (Step E); and8-acetyl-8-phenyl-12-hydroxynonadecanoic acid (Step F).

EXAMPLE 21 Preparation of8-Acetyl-8-phenyl-12-hydroxy-12-methylheptadecanoic Acid Step A:Preparation of 3-Phenyl-7-methyl-6-dodecen-2-one.

By following the procedure of Example 3, Step C, but substituting1-chloro-4-methyl-3-nonene for the 1-chloro-4-benzyloxynonane thereinemployed, there is obtained 3-phenyl-7-methyl-6-dodecen-2-one.

Step B: Preparation of Ethyl8-Acetyl-8-phenyl-12-methyl-11-heptadecenoate

By following the procedure of Example 3, Step D, but substituting3phenyl-7-methyl-6-dodecen-2-one for the3-phenyl-7-benzyloxy-2-dodecanone therein employed, there is obtainedethyl 8-acetyl-8-phenyl-12-methyl-11-heptadecenoate.

Step C: Preparation of 8-Acetyl-8-phenyl-12-methyl-11-heptadecenoic Acid

By following the hydrolytic procedure of Example 3, Step E, butsubstituting ethyl 8-acetyl-8-phenyl-12-methyl-11-heptadecenoate for theethyl 8-acetyl-8-phenyl-12-benzyloxyheptadecanoate therein employed,there is obtained 8-acetyl-8-phenyl-12-methyl-11-heptadecenoic acid.

Step D: 8-Acetyl-8-phenyl-12-hydroxy-12-methyl-heptadecanoic Acid

Mercuric acetate (3.8 g., 0.012 mole) is dissolved in water (12ml.) andtetrahydrofuran (20 ml.) is added to give a suspension of a yellowsolid. Then, 8-acetyl-8-phenyl-12-methyl-11-heptadecenoic acid (4.8 g.,0.012 mole) in tetrahydrofuran (20 ml.) is added, and the mixturestirred at room temperature for 24 hours. After 6 hours, the yellowsuspended solid has disappeared and a cloudy solution results. To thesolution is added 3M sodium hydroxide solution (12 ml.), followed by0.5M sodium borohydride solution in 3M solution hydroxide (12 ml.).Liquids are decanted from the precipitated mercury. The organic layer istaken up in ether, washed with three portions of water and dried oversodium sulfate. Evaporation of the ether leaves8-acetyl-8-phenyl-12-hydroxy-12-methyl-heptadecanoic acid as a yellowviscous oil which is purified by chromatrography on silica gel with 4%methanol in chloroform as eluant.

EXAMPLE 22 Preparation of 8-Acetyl-8-chloro-12-acetoxyheptadecanoic Acid

A mixture of 8-acetyl-8-chloro-12-hydroxyheptacecanoic acid (9.1 g.,0.025 mole) and acetic anhydride (6.1 g., 0.06 mole) is heated at 60° C.for 18 hours. The mixture is then cooled and dissolved in 80 ml. ethylether. The solution is extracted with an ice-cold solution of 8 g.sodium hydroxide in 150 ml. water. The basic solution is separated andacidified with concentrated hydrochloric acid. The oily acid whichseparates is taken up in ether, washed with water and dried over sodiumsulfate. The ether is evaporated to leave 9.0 g. of the oily crudeproduct.

The product is purified by chromatography on a column containing 150 g.of silica gel and with 1 % methanol in chloroform as the elutingsolvent. There is obtained 8-acetyl-8-chloro-12-acetoxyheptadecanoicacid, a colorless viscous oil.

EXAMPLE 23 Preparation of Methyl8-Acetyl-8-chloro-12-hydroxyheptadecanoate

A solution of diazomethane (approx. 2.5 g., 0.06 mole) in ether (100ml.) is mixed with a solution of8-acetyl-8-chloro-12-hydroxyheptadecanoic acid (10.9 g., 0.03 mole) inether (50 ml.). The resulting solution is allowed to stand 4 hours atroom temperature. Acetic acid is then added to destroy the excessdiazomethane and the solution is washed with dilute sodium bicarbonatesolution and water and dried over sodium sulfate. Evaporation ofvolatile materials at reduced pressure yields methyl8-acetyl-8-chloro-12-hydroxyheptadecanoate, a colorless viscous oil.

EXAMPLE 24 Preparation of N-[2-(Dimethylamino)ethyl]-8-acetyl-8-phenyl-12-hydroxyheptadecanamide

A solution of 8-acetyl-8-phenyl-12-hydroxyheptadecanoic acid (4.04 g.,10 millimole), Example 1, Step D, triethylamine (1.74 ml., 12.5millimole) and distilled water (18 ml., 1.0 mole) in acetonitrile (100ml.) is treated with N-t-butyl-5-methylisoxazolium perchlorate (3.0 g.,12.5 millimole). The resulting solution is evaporated in vacuo (wateraspirator) at 20°-23° C. for 4 hours providing a tacky residue which istriturated with water (150 ml.) at 0°-5° C. for 15 minutes. Afterdecanting the aqueous phase, the oily residue is dissolved inbenzene-ether [(1:1), 200 ml.]. The organic extract is dried over sodiumsulfate, filtered and evaporated in vacuo at 35°-40° C. providing thedesired "active ester",N-t-butyl-3-(8-acetyl-8-phenyl-12-hydroxyheptadecanoyloxy)crotonamide,as a pale yellow oil.

A solution of 2-dimethylaminoethylamine (0.88 g., 10 millimole) inacetonitrile (25 ml.) is added to a solution of the "active ester" inacetonitrile (25 ml.) providing a clear solution which is stirred at 25°C. for 17 hours. The solvent is removed in vacuo at 40°-50° C. leaving aresidual oil which is partitioned between ether (200 ml.) and water (2 ×100 ml.). The organic extract is washed with saturated brine (2 × 100ml.), dried over sodium sulfate, filtered and evaporated in vacuo at40°-50° C. providing a tan, crude oil.

The oil is partitioned between 5% hydrochloric acid (100 ml.) and ether(2 × 100 ml.). The aqueous acid phase is slowly basicified with sodiumbicarbonate (16.8 g., 0.2 mole), then with 40% aqueous sodium hydroxide(10 ml.) providing a heterogeneous mixture which is extracted with ether(200, 100 ml.). The organic extract is washed with saturated brine (200ml.), dried over sodium sulfate, filtered and evaporated in vacuo at40°-50° C. leaving the title compound as a pale yellow oil. (2.8 g.,76%); pmr (CDCl₃) δ 0.88 (3H,t).

EXAMPLE 25

    ______________________________________                                        Capsule Formulation                                                           ______________________________________                                        8-Acetyl-8-methyl-12-hydroxyhepta-                                             decanoic Acid             50     gm.                                         Stearic Acid (U.S.P. triple pressure)                                                                    125    gm.                                         Pluronic F-68              7.5    gm.                                         Corn starch                125    gm.                                         ______________________________________                                    

The stearic acid and pluronic are united in a vessel and melted using awater bath at 60°-65° C. The heating is discontinued and the8-acetyl-8-methyl-12-hydroxyheptadecanoic acid is dispersed into themixture and the corn starch is added with stirring which is continueduntil the mixture cools to ambient temperature. The mixture is reducedto granules by screening and placed in a number of 0 hard gelatincontaining 307.5 mg. of total solids and 50 mg. of the compound percapsule.

EXAMPLE 26

    ______________________________________                                        Parenteral Formulation of a Multidose Solution for                             Intramuscular and Intravenous Use                                            ______________________________________                                        8-Acetyl-8-chloro-12-hydroxyhepta-                                             decanoic Acid         1 gram                                                 Tris(hydroxymethyl)amino-                                                      methane               q.s. to adjust solu-                                   (Reagent Grade Tham)    tion to pH 7.4                                        Sodium chloride (U.S.P.)                                                                             q.s. to yield iso-                                                             tonic solution                                        Methylparaben          10 mg.                                                 Propylparaben           1 mg.                                                 Distilled water (pyrogen-free)                                                                       q.s. to 10 ml.                                         ______________________________________                                    

The 8-acetyl-8-chloro-12-hydroxyheptadecanoic acid suspended in about 6ml. of the water is treated with tris(hydroxymethyl)aminomethane withstirring until the pH reaches 7.4. The methylparaben and propylparabenare added with stirring and sufficient sodium chloride added to producean isotonic solution. After water is added to bring the final volume to10 ml., the solution is sterilized by membrane filtration and placed ina vial by an aseptic technique. The solution contains the Tham salt of8-acetyl-8-chloro-12-hydroxyheptadecanoic acid equivalent to 100 mg./ml.of the free acid.

EXAMPLE 27

    ______________________________________                                        Preparation of Suppositories                                                  ______________________________________                                        8-Acetyl-8-bromo-12-hydroxyhepta-                                              decanoic Acid             200    gm.                                         Butylated hydroxyanisole   82     mg.                                         Butylated hydroxytoluene   82     mg.                                         Ethylenediamine tetraacetic acid                                                                         163    mg.                                         Glycerine, U.S.P.          128    gm.                                         Sodium chloride, microfine 52.5   gm.                                         Polyethylene glycol 6000   128    gm.                                         Polyethylene glycol 4000   1269   gm.                                         ______________________________________                                    

The polyethylene glycol 4000 and polyethylene glycol 6000 were placed ina vessel surrounded by a water bath at such a temperature required tomaintain the melted contents at 60°-65° C. To the melt is added thebutylated hydroxyanisole and butylated hydroxytoluene with stirring.Then the ethylenediamine tetraacetic acid and microfine sodium chlorideare added to and dispersed in the mixture. The8-acetyl-8-bromo-12-hydroxyheptadecanoic acid is then added anddispersed into the mixture. Finally, the temperature is lowered to55°-60° C. and the glycerine added and dispersed.

While maintaining the temperature of 55°-60° C. and continuous mixing,the melt is dispersed into plastic suppository cavities of aconventional suppository cold-molding device. The suppositories thusprepared contain a total of 1.7778 gm. of contents of which 200 mg. are8-acetyl-8-bromo-12-hydroxyheptadecanoic acid.

What is claimed is:
 1. The compound having the following formula:##STR24## wherein R is carboxy, a carboxy salt, or --COOY wherein Y isalkyl having from 1-10 carbon atoms;A is ethylene, trimethylene,α-methylethylene, β-methylethylene, α,α-dimethylethylene, orα,α-dimethylethylene; Q is methyl, phenyl, or substituted phenyl; R¹ ishydrogen or methyl; R² is hydrogen or loweralkanoyl; R³ is hydrogen ormethyl; R⁴ is hydrogen, loweralkyl, or 2,2,2-trifluoroethyl; or, when R⁴is loweralkyl and R¹ is methyl, R⁴ and R¹ can be joined to form acarbocyclic ring with from 6 to 9 members; or when R⁴ is loweralkyl andR¹ is hydrogen, R⁴ can be joined to the carbon atom bearing R¹ or OR² toform a carbocyclic ring with from 5 to 8 members.
 2. The compound ofclaim 1 wherein R is carboxy, a carboxy salt having the formula:

    --COO.sup.- Me.sup.+

wherein Me is a pharmaceutically acceptable cation derived from a metalor an amine; or derivatized carboxy having the formula: --COOY, --conh₂,--conr⁶ r⁷, or --CONHNH₂ ;wherein Y is alkyl having 1-10 carbon atoms;R⁶ and R⁷ are each independently hydrogen, loweralkyl having 1-4 carbonatoms, or diloweralkylaminoalkyl having 4-7 carbon atoms.
 3. Thecompound of claim 2 wherein R is carboxy or a pharmaceuticallyacceptable carboxy salt.
 4. The compound of claim 3 which has theformula: ##STR25## wherein A is ethylene, trimethylene,α-methylethylene, β-methylethylene, α,α-dimethylethylene, orβ,β-dimethylethylene; R¹ is hydrogen or methyl; R⁷ is hydrogen,loweralkyl, or 2,2,2-trifluoroethyl; and Q is methyl, phenyl, orsubstituted phenyl.
 5. The compound of claim 4 wherein A is ethylene. 6.The compound of claim 5 wherein R⁷ is lower-alkyl or2,2,2-trifluoroethyl.
 7. The compound of claim 6 wherein R⁷ isloweralkyl having 2- 5 carbon atoms.
 8. The compound of claim 7 whereinA is ethylene, and R⁷ is ethyl.
 9. The compound of claim 8 wherein Q ismethyl and R¹ is hydrogen which is8-acetyl-8-methyl-12-hydroxyheptadecanoic acid.
 10. The compound ofclaim 8 wherein Q is phenyl and R¹ is hydrogen which is8-acetyl-8-phenyl-12-hydroxyheptadecanoic acid. 11.8-Acetyl-8-phenyl-12-hydroxynonadecanoic acid, the compound of claim 7wherein A is ethylene, R⁷ is butyl, Q is phenyl, and R¹ is hydrogen. 12.8-Acetyl-8-(4-fluorophenyl)-12-hydroxyheptadecanoic acid, the compoundof claim 8 wherein Q is 4-fluorophenyl and R¹ is hydrogen. 13.8-Acetyl-8-(2-methylphenyl)-12-hydroxyheptadecanoic acid, the compoundof claim 8 wherein Q is 2-methylphenyl and R¹ is hydrogen. 14.8-Acetyl-8-(3,4-dichlorophenyl)-12-hydroxyheptadecanoic acid, thecompound of claim 8 wherein Q is 3,4-dichlorophenyl and R¹ is hydrogen.15. 8-Acetyl-8-(4-methoxyphenyl)-12-hydroxyheptadecanoic acid, thecompound of claim 8 wherein Q is 4-methoxyphenyl and R¹ is hydrogen. 16.8-Acetyl-8-methyl-12-hydroxy-17,17,17-trifluoroheptadecanoic acid, thecompound of claim 6 wherein Q is methyl, A is ethylene, R¹ is hydrogenand R⁷ is 2,2,2-trifluoroethyl.
 17. The compound of claim 3 which hasthe formula: ##STR26## wherein A is ethylene, trimethylene, α-methylene,β-methylethylene, α,α-dimethylethylene, or β,β-dimethylethylene; R⁷ ishydrogen, loweralkyl of 1- 4 carbon atoms, or 2,2,2-trifluoroethyl; andQ is methyl or phenyl. 18.8-Acetyl-8-phenyl-12-hydroxy-12-methylheptadecanoic acid, the compoundof claim 17 wherein A is ethylene, R⁷ is ethyl, and Q is phenyl.
 19. Thecompound of claim 3 which has the formula: ##STR27## in which A isethylene, trimethylene, α-methylethylene, β-methylethylene,α,α-dimethylethylene, or β,β-dimethylethylene; R⁷ is hydrogen,loweralkyl, or 2,2,2-trifluoroethyl; and R² is loweralkanoyl orhydrogen.
 20. The compound of claim 2 which has the formula: ##STR28##wherein A is ethylene; R¹ is methyl or hydrogen; R⁴ is hydrogen,loweralkyl, or 2,2,2-trifluoroethyl; Y is alkyl having 1-10 carbonatoms; and Q is methyl or phenyl.
 21. The compound of claim 3 which hasthe formula: ##STR29## wherein A is ethylene, trimethylene,α-methylethylene, β-methylethylene, α,α-dimethylethylene, orβ,β-dimethylethylene; R⁷ is hydrogen, loweralkyl, or2,2,2-trifluoroethyl; and Q is methyl or phenyl.
 22. The compound ofclaim 3 which has the formula: ##STR30## wherein A is ethylene,trimethylene, α-methylethylene, β-methylethylene, α,α-dimethylethylene,or β,β-dimethylethylene; R¹ is hydrogen or methyl; R³ is hydrogen ormethyl; R⁴ is hydrogen, loweralkyl, or 2,2,2-trifluoroethyl; and Q ismethyl or phenyl; or when R⁴ is loweralkyl and R¹ is methyl, R⁴ and R¹are joined to form a carbocyclic ring with from 6 to 9 members; or whenR⁴ is loweralkyl and R¹ is hydrogen, R⁴ is joined to the carbon atombearing R¹ and OH to form a carbocyclic ring with from 5 to 8 members.